AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28350759 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (75 mg, twice daily)
Number of subjects: 80
Study 28350759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25183409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal drainage
Number of subjects: 137
Study 25183409 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 137
Study 24353564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates exercise program (8 weeks, 3 times weekly)
Number of subjects: 50
Study 24353564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured exercises)
Number of subjects: 50
Study 21529375 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRET)
Number of subjects: 20
Study 21529375 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 20
Study 17365072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive hypnotherapy (CH)
Number of subjects: 84
Study 17365072 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 84
Study 15838655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 21
Study 15838655 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 21
Study 15838655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Number of subjects: 21
Study 15838655 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study 12060028 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 31
Study 12060028 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 31
Study 9797850 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH administration (100 micrograms hCRH)
Number of subjects: 30
Study 7658052 — intervention group
Group type: EXPERIMENTAL
Intervention: ganciclovir
Number of subjects: 48
Study 7658052 — intervention group
Group type: EXPERIMENTAL
Intervention: foscarnet
Number of subjects: 48
Study 7658052 — intervention group
Group type: COMPARATOR
Intervention: maintenance therapy
Number of subjects: 48
Study 2732449 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (rIFN alpha)‐2A, administered intramuscularly in doses ranging from 1.5 MU to 20 MU/m2 of body surface, two or three times weekly during 4‐6 months.
Number of subjects: 58
Study 2732449 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (rIFN alpha)‐2A
Number of subjects: 58
Study 1184491 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-cost plus reinforcement
Number of subjects: 15
Study 1184491 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-cost only
Number of subjects: 15
Study 1184491 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 15
Study 28818850 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDCER ICF
Number of subjects: 234
Study 28818850 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICF
Number of subjects: 234
Study 27777439 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS Sonopsy CY®
Number of subjects: 0
Study 27777439 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle
Number of subjects: 0
Study 24894546 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity Toric
Number of subjects: 20
Study 24894546 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear Toric
Number of subjects: 20
Study 24894546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Advance for Astigmatism
Number of subjects: 20
Study 24894546 — intervention group
Group type: COMPARATOR
Intervention: Air Optix for Astigmatism
Number of subjects: 20
Study 24894546 — intervention group
Group type: COMPARATOR
Intervention: PureVision Toric
Number of subjects: 20
Study 22298121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 42
Study 22298121 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100-200 mg/day)
Number of subjects: 42
Study 22298121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20227721 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA/ARA-supplemented formula
Number of subjects: 89
Study 20227721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 18983318 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate restoration of single implants placed at the time of tooth extraction (test group)
Number of subjects: 16
Study 18983318 — intervention group
Group type: COMPARATOR
Intervention: Immediate restoration of single implants placed 8 weeks after tooth extraction (control group)
Number of subjects: 16
Study 16098300 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors during TAXUS stent implantation
Number of subjects: 0
Study 16098300 — intervention group
Group type: COMPARATOR
Intervention: Control stent without GP IIb/IIIa inhibitors
Number of subjects: 0
Study 14533561 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation or optimal dietary calcium intake
Number of subjects: 0
Study 11104295 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained‐release nifedipine
Number of subjects: 158
Study 11104295 — intervention group
Group type: COMPARATOR
Intervention: pill placebo
Number of subjects: 158
Study 11104295 — intervention group
Group type: COMPARATOR
Intervention: electromyography
Number of subjects: 158
Study 11104295 — intervention group
Group type: COMPARATOR
Intervention: temperature biofeedback
Number of subjects: 158
Study 8934156 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea-membrane test
Number of subjects: 99
Study 8934156 — intervention group
Group type: COMPARATOR
Intervention: Urea-gel method
Number of subjects: 99
Study 1455381 — intervention group
Group type: EXPERIMENTAL
Intervention: tactivin
Number of subjects: 31
Study 1455381 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 31
Study 6384289 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil for 12 months
Number of subjects: 15
Study 6384289 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical minoxidil for 12 months
Number of subjects: 15
Study 31129108 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep parameters (total PSQI score)
Number of subjects: 72
Study 31129108 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep parameters (PSQI-sleep medication)
Number of subjects: 72
Study 31129108 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep parameters (PSQI-subjective sleep quality, PSQI-sleep latency, PSQI-sleep duration, PSQI-daytime dysfunction)
Number of subjects: 72
Study 31129108 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI-daytime dysfunction
Number of subjects: 72
Study 31129108 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI-subjective sleep quality
Number of subjects: 72
Study 31129108 — intervention group
Group type: EXPERIMENTAL
Intervention: Global PSQI subjective sleep parameters
Number of subjects: 72
Study 29378045 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk vitamin B-12 concentration
Number of subjects: 100
Study 29378045 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant serum vitamin B-12 concentration
Number of subjects: 100
Study 29378045 — intervention group
Group type: COMPARATOR
Intervention: Maternal milk vitamin B-12 concentrations
Number of subjects: 100
Study 26818974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID or 10 mg BID
Number of subjects: 486
Study 24742124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) 2 g/d
Number of subjects: 90
Study 24742124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Oral Contraceptive Pills (M+OCP)
Number of subjects: 90
Study 24742124 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 90
Study 24742124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 90
Study 22883485 — intervention group
Group type: EXPERIMENTAL
Intervention: cART containing Tenofovir and a non-nucleoside reverse-transcriptase-inhibitor (TFV/NNRTI)
Number of subjects: 317
Study 22883485 — intervention group
Group type: EXPERIMENTAL
Intervention: cART containing Tenofovir and a protease-inhibitor (TFV/PI)
Number of subjects: 317
Study 22883485 — intervention group
Group type: COMPARATOR
Intervention: cART without Tenofovir
Number of subjects: 317
Study 22883485 — intervention group
Group type: COMPARATOR
Intervention: No cART
Number of subjects: 317
Study 19840829 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid resin composite (Clearfil AP‐X; AP)
Number of subjects: 22
Study 19840829 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Clearfil Flow FX; FX)
Number of subjects: 22
Study 19840829 — intervention group
Group type: COMPARATOR
Intervention: Both AP and FX
Number of subjects: 22
Study 17894540 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 34
Study 17894540 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled cold water
Number of subjects: 34
Study 17894540 — intervention group
Group type: COMPARATOR
Intervention: BAL fluid analysis
Number of subjects: 34
Study 17894540 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 34
Study 15668765 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cmH(2)O PEEP
Number of subjects: 12
Study 15668765 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cmH(2)O PEEP
Number of subjects: 12
Study 15668765 — intervention group
Group type: COMPARATOR
Intervention: Control (non-recruiters)
Number of subjects: 12
Study 11744653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual cyclodextrin androstenediol (Sl Diol) 20 mg
Number of subjects: 8
Study 11744653 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 8
Study 10512399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed cow's milk protein formula
Number of subjects: 15
Study 10512399 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm infant formula
Number of subjects: 15
Study 8547937 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding 2 (69 g CHO/400 ml)
Number of subjects: 6
Study 1714761 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (10,000 international units)
Number of subjects: 0
Study 1714761 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 ml)
Number of subjects: 0
Study 6412271 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride morning only dose
Number of subjects: 18
Study 6412271 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride daily total dose in two equal fractions at 8 a.m. and 4 p.m.
Number of subjects: 18
Study 6412271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31276747 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealants
Number of subjects: 41
Study 31276747 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer sealants
Number of subjects: 41
Study 29061504 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus S‐1 (IRI‐S)
Number of subjects: 105
Study 29061504 — intervention group
Group type: COMPARATOR
Intervention: S‐1 therapy
Number of subjects: 105
Study 29061504 — intervention group
Group type: EXPERIMENTAL
Intervention: IRI‐S
Number of subjects: 105
Study 29061504 — intervention group
Group type: COMPARATOR
Intervention: S‐1
Number of subjects: 105
Study 27669109 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser 532 nm
Number of subjects: 19
Study 27669109 — intervention group
Group type: COMPARATOR
Intervention: Long pulsed Nd:YAG laser 1,064 nm
Number of subjects: 19
Study 23235716 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) for 12 weeks
Number of subjects: 21
Study 23235716 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 21
Study 23235716 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 21
Study 21562067 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg + glyburide 7.5 mg
Number of subjects: 768
Study 21562067 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg + glyburide 7.5 mg
Number of subjects: 768
Study 21562067 — intervention group
Group type: COMPARATOR
Intervention: up-titrated glyburide
Number of subjects: 768
Study 21562067 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg
Number of subjects: 768
Study 21562067 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg
Number of subjects: 768
Study 19595557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (8 healthy-eating classes, 10 physical-activity classes, 6 telephone-counseling sessions over 9 months)
Number of subjects: 450
Study 19595557 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 450
Study 16549457 — intervention group
Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]leucine at 65 mg/(kg.d)
Number of subjects: 7
Study 16549457 — intervention group
Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]leucine at 45 mg/(kg.d)
Number of subjects: 7
Study 16549457 — intervention group
Group type: COMPARATOR
Intervention: L-[1-(13C)]lysine (control)
Number of subjects: 7
Study 12775372 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned rice (CR)
Number of subjects: 0
Study 12775372 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned rice meal with pork sausage (CRM)
Number of subjects: 0
Study 12775372 — intervention group
Group type: COMPARATOR
Intervention: Canned rice (CR) and canned rice meal with pork sausage (CRM)
Number of subjects: 0
Study 10681363 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV) monotherapy
Number of subjects: 30
Study 9196609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF) 15 mg twice daily for 7 days
Number of subjects: 16
Study 9196609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9196609 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 micrograms/kg i.v.)
Number of subjects: 16
Study 9196609 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin releasing hormone (CRH) (1 microgram/kg i.v.)
Number of subjects: 16
Study 8453437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, three times a day for six weeks)
Number of subjects: 12
Study 8453437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8453437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (continued for another six weeks)
Number of subjects: 12
Study 8453437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (continued for another six weeks)
Number of subjects: 12
Study 3743143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal occlusion with petrolatum gauze
Number of subjects: 8
Study 3743143 — intervention group
Group type: COMPARATOR
Intervention: Nose open (control)
Number of subjects: 8
Study 3743143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal occlusion
Number of subjects: 8
Study 29603242 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentoring program
Number of subjects: 47
Study 26547424 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus paclitaxel (daily oral S‐1 at 80 mg/m² for 2 weeks plus paclitaxel at 50 mg/m² on days 1 and 8, every 3 weeks)
Number of subjects: 78
Study 26547424 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (weekly administration at 80 mg/m² three times every 4 weeks)
Number of subjects: 78
Study 26547424 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus paclitaxel
Number of subjects: 78
Study 26547424 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 78
Study 24293120 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention (activity coach with 3D-accelerometer and smartphone) for 4 weeks
Number of subjects: 34
Study 24293120 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention
Number of subjects: 34
Study 24293120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 34
Study 22876444 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese yam-epimedium mixture
Number of subjects: 49
Study 22876444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20464817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 14
Study 20464817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IMT)
Number of subjects: 14
Study 18387656 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP (Q4)
Number of subjects: 298
Study 18387656 — intervention group
Group type: EXPERIMENTAL
Intervention: Other biomarkers (hsCRP, MMP‐9, PAPP‐A, MPO, sCD40L, FM)
Number of subjects: 298
Study 17925000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 467
Study 17925000 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment (controls)
Number of subjects: 467
Study 15717139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.3 mg/kg daily
Number of subjects: 46
Study 15717139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.6 mg/kg daily
Number of subjects: 46
Study 15717139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Cisapride)
Number of subjects: 46
Study 15717139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride treatment
Number of subjects: 46
Study 11598607 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with added soy fiber
Number of subjects: 45
Study 11598607 — intervention group
Group type: COMPARATOR
Intervention: Regular soy formula (without added fiber)
Number of subjects: 45
Study 9393335 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell DTP vaccine (n = 20,720)
Number of subjects: 82892
Study 9393335 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-component acellular DTP vaccine (n = 20,747)
Number of subjects: 82892
Study 9393335 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-component acellular DTP vaccine (n = 20,728)
Number of subjects: 82892
Study 9393335 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component acellular DTP vaccine (n = 20,697)
Number of subjects: 82892
Study 7514842 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSA (polyclonal antibodies)
Number of subjects: 421
Study 7514842 — intervention group
Group type: COMPARATOR
Intervention: MPSA (monoclonal antibodies)
Number of subjects: 421
Study 3605184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg per day of warfarin for 18 months
Number of subjects: 4
Study 3605184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 10651597 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and standardized knee exercise program
Number of subjects: 83
Study 10651597 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic ultrasound to the knee
Number of subjects: 83
Study 30472808 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 1198
Study 30472808 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of proton pump inhibitors
Number of subjects: 1198
Study 29486493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside Paediatric Early Warning System (BedsidePEWS)
Number of subjects: 144539
Study 29486493 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no severity of illness score)
Number of subjects: 144539
Study 26662809 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dimensional Treatment Foster Care (MTFC)
Number of subjects: 171
Study 26662809 — intervention group
Group type: COMPARATOR
Intervention: Usual care (TAU)
Number of subjects: 171
Study 24436354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (70 mL of concentrated beetroot juice containing a minimum of 0.3 g of nitrate)
Number of subjects: 16
Study 24436354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (70 mL of placebo)
Number of subjects: 16
Study 22810982 — intervention group
Group type: COMPARATOR
Intervention: MNP group (maize porridge with multi-micronutrient powder containing 2.5 mg iron as NaFeEDTA; 6.6 mg iron/meal)
Number of subjects: 279
Study 22810982 — intervention group
Group type: COMPARATOR
Intervention: Amaranth group (unrefined maize 30% and amaranth grain 70% porridge; 23 mg iron/meal)
Number of subjects: 279
Study 22810982 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrefined maize porridge; 4.1 mg iron/meal)
Number of subjects: 279
Study 20599002 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day and Ezetimibe 10 mg/day
Number of subjects: 100
Study 16920077 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1.5 g/d; .84 g/d eicosapentaenoic acid, .7 g/d docosahexaenoic acid)
Number of subjects: 13
Study 16920077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on ZEEPe
Number of subjects: 10
Study 16247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on PEEPe
Number of subjects: 10
Study 16247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PEEPe and fenoterol
Number of subjects: 10
Study 12453332 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 twice daily for 14 days, every 3 weeks)
Number of subjects: 0
Study 12453332 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 10433619 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 10 sunscreen (n = 44)
Number of subjects: 87
Study 10433619 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 30 sunscreen (n = 42)
Number of subjects: 87
Study 7887554 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (one double‐strength tablet daily, five times a week)
Number of subjects: 60
Study 7887554 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 60
Study 7887554 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 60